The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders
Author:
Affiliation:
1. National Engineering Research Center for Strategic Drugs, Beijing Institute of Pharmacology and Toxicology, Beijing, China
Funder
New Drugs Innovation and Development
Publisher
Informa UK Limited
Subject
Drug Discovery,Pharmacology,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/13543776.2023.2262176
Reference93 articles.
1. Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
2. Toward personalized treatment approaches for non-small-cell lung cancer
3. EGFR signaling pathway as therapeutic target in human cancers
4. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
5. Overcoming therapy resistance in EGFR-mutant lung cancer
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Encouraging Fussy Eaters in EGFR-Mutated Lung Cancer;Journal of Thoracic Oncology;2024-08
2. Kinase inhibitors: 20 years of success and many new challenges and recent trends in their patents;Expert Opinion on Therapeutic Patents;2024-05-24
3. Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives;International Journal of Molecular Sciences;2024-05-17
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3